The company is currently building out its product portfolio to include additional cytokine profiling panels as well as tools for single-cell phosphoproteomics.
Bruker has postponed reporting of its final Q4 and full-year 2019 results, but reported preliminary Q4 revenues of $599.9 million and full-year revenues of $2.07 billion.
A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.
